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targeted in this analysis. ConClusions: Prospective inclusion of health-economic 
endpoints in clinical trials for PAD is important to support future decision-making 
by payers and providers. The OPTIMIZE study collects targeted information on qual-
ity of life and resource utilization to facilitate future health-economic analyses.
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objeCtives: Dexmedetomidine was approved for ICU sedation in adults in the 
EU in 2011, but has been available in other countries since 1999 and used in many 
different clinical situations including in children. This study evaluated off-label 
use of dexmedetomidine in usual care in the EU. Methods: A chart review DUS 
of patients treated with dexmedetomidine was conducted in 16 hospitals across 
Austria, Finland, Germany and Poland. Patients were identified either prospectively 
or retrospectively, with anonymised data abstraction performed retrospectively 
post-administration. Chart data on patient demographics, indication, dexmedetomi-
dine administration, concomitant medications and therapeutic effectiveness were 
collected via an electronic data collection tool. Results: 2,000 patients received 
2,159 administrations of which 36.6% contained elements not according to the 
SmPC. Collecting off-label use was a concern to some sites and ethics committees, 
resulting in high site attrition and relatively slow start-up. Collecting sufficient 
mature dexmedetomidine use early after launch required focus on prolific users, 
while excluding regions where dexmedetomidine uptake was slow. Site selection 
was performed blinded by the Steering Committee to avoid bias. The study required 
collaboration across many hospital departments. Varied medical records systems 
required site-specific approaches to patient identification; some sites performing 
database searches, others using a manual process. Restricted access to records of 
patients from other hospital departments in some cases necessitated completion of 
paper worksheets by non-study hospital staff. Anonymised data collection avoided 
the need for informed consent but precluded patient verification and data queries, 
thus robust electronic data checks were essential. Data were regularly reviewed 
for evidence of duplication of patients within sites. ConClusions: Chart review 
DUS was successful in investigating off-label dexmedetomidine prescribing. Study 
conduct flexibility was essential to meet different needs of study sites and ensure 
study success. Close attention to potential sources of bias was required to ensure 
a robust outcome.
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objeCtives: The choice of comparator drug is a critical factor in successful mar-
ket access, pricing and reimbursement by national payer bodies. Varying require-
ments specified for the comparator selected have led to approaches that differ by 
country. Legislation introduced in Germany in particular has affected studies in 
progress. As HTA agencies differ per country, the objective of the analysis which 
covers Germany, UK and France is twofold: - Do market access regulations influ-
ence trial design? - Do the chosen trial designs cover national pricing and reim-
bursement regulations? Methods: Published benefit assessments from selected 
HTA agencies websites such as G-BA, NICE and HAS were used to analyze diabetes 
drug assessments in terms of requested comparators and final recommendation. 
Furthermore, Clincialtrials.gov was used to analyze the trials in diabetes and their 
design. Results: Of the 49 HTA assessments by G-BA, HAS and NICE analyzed, 
10 assessments (20%) had an inappropriate comparator chosen. This resulted in 
eight negative recommendations, one positive with restrictions and one positive 
recommendation. Most of the HTA assessments with a positive outcome presented 
head-to-head or adjusted indirect comparisons. Unadjusted indirect comparisons 
were mainly rejected; and a mixed approach was allowed in France and England but 
not recommended in Germany. ConClusions: Having solely marketing authoriza-
tion (EMA) in mind when designing a trial can lead to an unsuccessful drug launch 
with regards to national pricing and reimbursement decisions. More specifically, 
the choice of comparator is considered as the most important factor for benefit 
assessment in Germany and the methodology applied is crucial to obtaining a posi-
tive outcome. In France and England, the use of specific guidelines for the choice 
of comparators and comparison methodology developed by NICE and validated by 
the HAS, is particularly relevant to obtain a positive outcome.
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objeCtives: Management of symptomatic diabetic peripheral neuropathy (DPN) 
is complicated by a lack of evidence regarding the comparative effectiveness of 
available agents, frequent side effects, and the need for ongoing symptom assess-
objeCtives: To compare trials of the four anti-epileptic drugs (AEDs) approved 
specifically for the adjunctive treatment of primary generalized tonic-clonic sei-
zures (PGTCS): topiramate [TPM] (1999), lamotrigine [LTG] (2006), levetiracetam [LEV] 
(2007), lamotrigine-XR [LTG-XR] (2010), and perampanel [PER] (2015). Methods: 
Trial data were identified through a systematic literature review. Main inclusion 
criteria: randomized, controlled, PGTCS with or without other generalized seizure 
types, and published 1989-2014. Key exclusion criteria: predominantly children/
adolescents and intravenous drug study. Data were abstracted from indexed pub-
lications, clinicaltrials.gov, and regulatory reports of the United States Food and 
Drug Administration and European Medicines Agency. Results: Five PGTCS trials 
[TPM-RCT (n= 80), LTG-RCT (n= 117), LEV-RCT (n= 164), LTG-XR-RCT (n= 146), PER-RCT 
(n= 163)] were identified. All trials were placebo-controlled where baseline AEDs 
were continued into the trial and consisted of the standard of care (SOC) at the time. 
Trial designs were similar with minor exceptions: PER-RCT allowed 1-3 baseline 
AEDs (others 1-2), LEV-RCT and PER-RCT had shorter titration periods (4 versus 7 & 8 
weeks), and LEV-RCT had the longest maintenance period (20 versus 12 & 13 weeks). 
Baseline PGTCS frequency was similar between trials except TPM-RCT which was 
higher (4.5-5.0 versus 2.3-3.0 per 28 days). The presence of LTG, LEV, and zonisamide 
in the SOC increased over time while the use of carbamazepine, phenytoin, and 
phenobarbital decreased. Valproate and TPM use fluctuated but appeared stable. In 
the latest phase III trial, PER-RCT had the following SOC composition, 43% valproate, 
39% LTG, 15% TPM, 31% LEV, 12% zonisamide, 8% carbamazepine, 6% phenytoin, and 
4% phenobarbital. ConClusions: Our review indicates that while the trial designs 
have remained similar over time, the SOC has evolved with the approval of new 
PGTCS medications. The latest trial, PER-RCT, has an SOC that is comprised heavily 
of the most recently approved PGTCS drugs.
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objeCtives: Guidance and standards are made available by the European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) as refer-
ence tools for methodology and transparency of post-authorization studies. They 
are cited by the Guideline on good pharmacovigilance practices (GVP) Module 
VIII as relevant scientific guidances. Here we report an analysis conducted on 
Pharmacovigilance Risk Assessment Committee (PRAC) minutes regarding meth-
odological issues. Methods: All publicly available minutes of PRAC meetings from 
July 2012 to March 2015 were considered. The number of submitted post-authoriza-
tion safety study (PASS) protocols requiring endorsement was recorded (excluding 
advices), as well as endorsement/ refusal and reason. ENCePP documentation was 
consulted. Results: From July 2012 to March 2015, 33 PASS protocols submitted to 
PRAC requiring endorsement were considered, increasing with years: 2 in 2012, 8 
(17 considering resubmissions) in 2013, 18 (24 considering resubmissions) in 2014. 
The total number of evaluations was 54. Thirteen were endorsed at the first step 
(including endorsement with changes requested), while 20 required at least one 
amendment reaching approval up to 15 months after submission. The most com-
mon reasons for refusal concerned study design (20 cases), mainly reporting designs 
not allowing to fulfil study objectives (N= 14). Furthermore, PRAC review asked for 
alternatives to reduce bias and confounding (N= 2), simplifications aiming at rein-
forcing the observational nature of the study (N= 1), further justification of sample 
size (N= 1) and considerations on feasibility (N= 1). From 2013 to 2014 an increasing 
number of endorsed PASS protocols was observed (7/17 and 12/24 respectively). 
During the same years ENCePP Checklist for Study Protocols and ENCePP Guide 
on Methodological Standards in Pharmacoepidemiology were reviewed, and the 
number of studies included in the ENCePP e-register increased. ConClusions: 
An increasing use of guidance and standards will allow strengthening robustness 
of design and results of observational studies.
PRM230
econoMic study design foR the oPtiMize study on oRbital 
atheRectoMy and dRug-coated balloon devices foR the tReatMent 
of beloW-the-knee PeRiPheRal aRteRial disease
Martinsen BJ1, Weber SA2, Pietzsch ML2, Behrens A1, Weatherspoon M1, Igyarto Z1,  
Zhao R3, Kotlarz H1, Pietzsch JB4
1Cardiovascular Systems, Inc., St. Paul, MN, USA, 2Cellogic GmbH, Berlin, Germany, 3University of 
Minnesota, Minneapolis, MN, USA, 4Wing Tech Inc., Irvine, CA, USA
objeCtives: Present the economic study design of the OPTIMIZE study on orbital 
atherectomy system (OAS) and drug-coated balloon (DCB) treatment of peripheral 
artery disease (PAD) patients. Treating patients with calcified peripheral arterial 
lesions can be challenging and costly. The impact of OAS and DCBs in treating calci-
fied lesions has been studied independently. The objective of this study design is to 
assess the economic impact of treating below-the-knee (BTK) calcified PAD lesions 
with OAS+DCB compared to treating BTK calcified lesions with DCB alone (without 
OAS). Methods: This prospective, multi-center, post-market pilot study comparing 
OAS with adjunctive DCB angioplasty versus DCB angioplasty alone for treatment 
of calcified BTK lesions is a 1:1 randomized controlled study of 50 patients with 
calcification. In addition to clinical outcomes, health economic outcomes will be 
collected for the index procedure as well as additional procedures required during 
the clinical follow-up period. Results: Health economic outcomes will be meas-
ured at the index procedure, at 30 days, 3 months, 6 months, 12 months, and 24 
months post procedure for the treatment of PAD and its complications (repeat 
procedures, amputations, etc.). Health-related quality of life will be measured using 
the EQ-5D instrument. Resource utilization will be collected from case report forms 
and hospital accounting systems, using site-specific procedure code information 
of relevant OPS (German sites), CHOP (Swiss sites), and MEL codes (Austrian sites). 
Analyses from the third-party payer perspective will be informed by country-specific 
reimbursement amounts, using Germany as the initial reference case. Resulting cost 
difference and incremental cost-effectiveness are the main economic outcomes 
